Smart Lidocaine Gels for Pain Management

用于疼痛管理的智能利多卡因凝胶

• 批准号: 7273098
• 负责人: Chirakkal Krishnan
• 金额: $ 21.33万
• 依托单位: STONYBROOK TECHNOLOGY/APPLIED RESEARCH
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7273098
• 关键词: Affect; Alginates; Anesthetics; Animal Testing; Applied Research; Behavior; Biomedical Engineering; Body Temperature; Characteristics; Chitosan; Class; Complex; Drug Delivery Systems; Ethylene Oxide; Gel; In Vitro; Injection of therapeutic agent; Injury; Laboratories; Lasers; Lead; Lidocaine; Life; Local Anesthetics; Marketing; Methods; Microscopic; Modeling; Nanostructures; Nanotechnology; Pain; Pain management; Pathway interactions; Performance; Pharmaceutical Preparations; Phase; Phase Transition; Physiological; Pluronics; Property; Range; Rattus; Relative (related person); Research; Roentgen Rays; Site; System; Tail; Techniques; Technology; Testing; Therapeutic; Time; Treatment Efficacy; United States National Institutes of Health; Water; Week; base; chronic pain; controlled release; copolymer; day; design; dosage; in vivo; light scattering; nanostructured; particle; poly(propylene oxide); pressure; programs; self assembly; size; submicron

DESCRIPTION (provided by applicant): This Phase I proposal aims to develop a unique class of nanostructured smart lidocaine gels for site-specific pain management. The hypothesis for the design and testing of this gel system is based on two recent findings. (1) Medicated smart gels, containing lidocaine (an anesthetic drug) and mixtures of pluronic-based block copolymers (poly (ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide)) in water, can be fine-tuned by copolymer composition and concentration to possess thermo reversible gelation behavior near the body temperature. Such characteristics will enable the sustained and controlled release of lidocaine molecules and can facilitate site deployment pathways (e.g. low pressure spraying, injection or topical coating). (2) The dynamic formation of microscopic bioabsorbable medicated particles (micron and submicron sizes) based on polyelectrolyte complex formation (e.g., mixtures based on chitosan and alginate) can provide a sustained release of lidocaine to tens of days. To test the above hypothesis, three specific aims have been proposed to verify the scientific merits and technical feasibility of the approach. Specific Aim 1: Characterize and optimize therapeutic mixtures of lidocaine-pluronic smart gels and lidocaine containing polyelectrolyte complex particles with sustained lidocaine release capability (from days to weeks or perhaps even months). Specific Aim 2: In vitro assessments of the therapeutic efficacies of mixtures of lidocaine-pluronic smart gels, lidocaine-containing polyelectrolyte complex particles, and smart gels containing such complex particles. Specific Aim 3: Determination of the relative in vivo efficacies of lidocaine-containing smart gels by using two rat models based on the hot-plate test and the tail-flick test. The strength of the proposed system is its ability to manage pain through controlled and sustained release of local anesthetics at the injury site. The persistence of chronic pain can affect many different aspects of personal life, ranging from the physiological to societal and financial changes. This proposal aims to develop a unique class of smart lidocaine gels for pain management. The strength of the proposed system is its ability to manage pain through controlled and sustained release of local anesthetics at the injury site.

描述（由申请人提供）：本I期提案旨在开发一种独特的纳米结构智能利多卡因凝胶，用于部位特异性疼痛管理。该凝胶系统的设计和测试的假设基于两个最近的发现。(1)药物智能凝胶，含有利多卡因（麻醉药物）和pluronic为基础的嵌段共聚物（聚（环氧乙烷）-b-聚（环氧丙烷）-b-聚（环氧乙烷））在水中的混合物，可以微调共聚物的组成和浓度，以拥有接近体温的热可逆凝胶化行为。这些特性将使利多卡因分子能够持续和受控释放，并可促进部位部署途径（例如低压喷雾、注射或局部包衣）。(2)基于生物可吸收复合物形成的微观生物可吸收药物颗粒（微米和亚微米尺寸）的动态形成（例如，基于脱乙酰壳多糖和藻酸盐的混合物）可以提供利多卡因的持续释放达数十天。为了验证上述假设，提出了三个具体目标，以验证该方法的科学价值和技术可行性。具体目标1：表征并优化利多卡因-普朗尼克智能凝胶和含利多卡因的复合物颗粒的治疗混合物，该颗粒具有持续释放利多卡因的能力（从数天到数周甚至数月）。具体目标二：利多卡因-普朗尼克智能凝胶、含有利多卡因的聚乙二醇复合物颗粒和含有这种复合物颗粒的智能凝胶的混合物的治疗功效的体外评估。具体目标3：基于热板试验和甩尾试验的两种大鼠模型测定含利多卡因智能凝胶的相对体内功效。所提出的系统的优势在于其通过在损伤部位控制和持续释放局部麻醉剂来管理疼痛的能力。慢性疼痛的持续性可以影响个人生活的许多不同方面，从生理到社会和财务变化。该提案旨在开发一种独特的智能利多卡因凝胶用于疼痛管理。所提出的系统的优势在于其通过在损伤部位控制和持续释放局部麻醉剂来管理疼痛的能力。